Both in Pharmaceuticals
Entrada Therapeutics vs Keros Therapeutics
Over the past year TRDA returned −25.6% and KROS returned −22.9%; their daily moves had a correlation of 0.29.
TRDA −25.6% KROS −22.9%Growth of $1, one year, split-adjusted
| Metric | TRDA | KROS |
|---|---|---|
| Price | $4.37 | $10.66 |
| Market cap | $170.2M | $211.4M |
| Today | −8.58% | −3.96% |
| 1 month | −36.7% | −6.2% |
| 6 months | −68.8% | −8.7% |
| Year to date | −57.5% | −47.6% |
| 1 year | −29.4% | −26.4% |
| Revenue growth (YoY) | −53.9% | −100.0% |
| Gross margin | 100.0% | — |
| Net margin | −4762.0% | — |
| P/E (TTM) | — | — |
| Price / sales | 36.3× | 14.1× |
| Net cash | $223.0M | $257.6M |
| Dividend yield | — | — |
| Volatility (60d) | 72.7% | 45.5% |
| Short % of float | 11.9% | 6.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).